Blue Cell Therapeutics ApS
CVR 39981610 · Private limited company (ApS) · Active · High risk
Blue Cell Therapeutics ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 3.4% over the next 12 months, which is 2.4 times the average for Danish companies. 7 annual reports have been published, of which 4 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -8.1m and a net result of DKK -21.2m.
Bankruptcy risk for Blue Cell Therapeutics ApS
2.4 × the average (1.41%) · higher risk than 88% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 39981610
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (8 years)
- Address
- Ole Maaløes Vej 3, 3.
2200 København N - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 60k
- Auditor
- Grant Thornton, Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 4 of 7 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -168.5% |
| Current ratio | 36% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -5.8m | DKK -3.1m |
| Net profit | DKK -21.2m | DKK -15.2m |
| Equity | DKK -8.1m | DKK 13.1m |
| Total assets | DKK 4.8m | DKK 14.1m |
| Cash | DKK 190k | – |
| Short-term debt | DKK 13.0m | – |
| Avg. employees | 9 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · Grant Thornton, Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 186 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 178 | ||
| 1 Jan 2023 – 31 Dec 2023 | 191 | Late | |
| 1 Jan 2022 – 31 Dec 2022 | 170 | ||
| 1 Jan 2021 – 31 Dec 2021 | 172 | ||
| 1 Jan 2020 – 31 Dec 2020 | 202 | Late | |
| 28 Oct 2018 – 31 Dec 2019 | 252 | Late |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| Board | Søren Paludan Sheikh | Current | |
| Board | Michael Ulveman | Current | |
| Board | Anella Rogaczewski | Current | |
| Board | Ole Vahlgren | Current | |
| Board | Olav Hellebø | Current | |
| Board | Thomas Tofte Hansen | ||
| Board | Leif Helth Jensen | ||
| Board | Michael Ulveman | ||
| Board | André Rafal Rogaczewski | ||
| Board | Casper Tind Hansen | ||
| Board | Ole Vahlgren | ||
| Board | Ole Vahlgren | ||
| Board | Anders Vadsholt | ||
| Board | Sebastian Wehle | ||
| Owner (5%) | SEIER CAPITAL A/S | Current | |
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | Current | |
| Owner (33%) | SPSheikh Holding ApS | Current | |
| Owner (100%) | ynapmoc & etfot ApS | ||
| Owner (20%) | Leif Helth Jensen | ||
| Owner (5%) | SPLUSH GROUP ApS | ||
| Owner (50%) | SHEIKH HOLDING ApS | ||
| Owner (5%) | ynapmoc & etfot ApS | ||
| Owner (5%) | Leif Helth Jensen | ||
| Owner (67%) | SPSheikh Holding ApS | ||
| Owner (5%) | REGTISS ApS | ||
| Owner (5%) | TTH HOLDING ApS | ||
| Owner (20%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (50%) | SPSheikh Holding ApS | ||
| Owner (25%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (5%) | SEIER CAPITAL A/S | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Owner (5%) | SEIER CAPITAL A/S | ||
| Owner (33%) | ANDRÉ ROGACZEWSKI HOLDING II ApS | ||
| Owner (33%) | SPSheikh Holding ApS | ||
| Auditor | Grant Thornton, Godkendt Revisionspartnerselskab | Current | |
| Founder | ynapmoc & etfot ApS | Current |
Address history (1 moves)
| Ole Maaløes Vej 3, 3., 2200 København N | |
| c/o Tofte & Company ApS, Christian IX's Gade 7, 3., 1111 København K |
Former names
| Blue Cell Therapeutics ApS | – now |
| Regenerative Therapeutics IVS | – |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Blue Cell Therapeutics ApS
Has Blue Cell Therapeutics ApS gone bankrupt?
No, Blue Cell Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Blue Cell Therapeutics ApS?
Our model estimates a bankruptcy risk of 3.4% over the next 12 months (high risk), which is 2.4 times the average for Danish companies.
Who is the auditor of Blue Cell Therapeutics ApS?
Blue Cell Therapeutics ApS most recently used Grant Thornton, Godkendt Revisionspartnerselskab.
When was Blue Cell Therapeutics ApS founded?
Blue Cell Therapeutics ApS was founded on 28 October 2018.
What is the equity of Blue Cell Therapeutics ApS?
Equity was DKK -8.1m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.